ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - tramadolio hidrochloridas/paracetamolis - pailginto atpalaidavimo tabletės - 37,5 mg/325 mg; 75 mg/650 mg - tramadol and paracetamol

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

sun pharmaceutical industries europe b. v. - lansoprazolas - skrandyje neirios kietosios kapsulės - 30 mg - lansoprazole

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - lansoprazolas - skrandyje neirios kietosios kapsulės - 30 mg - lansoprazole

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

berlin-chemie ag (menarini group) - dapoksetinas - plėvele dengtos tabletės - 60 mg; 30 mg - dapoxetine

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

zakłady farmaceutyczne polpharma s.a. - sulfametoksazolas/trimetoprimas - geriamoji suspensija - 200 mg/40 mg/5 ml - sulfamethoxazole and trimethoprim

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - kiaušidžių navikai - antinavikiniai vaistai - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca yra nurodyta kaip monotherapy priežiūros gydymo suaugusių pacientų su platinos-jautrus atsinaujino aukštos kokybės epitelio, kiaušidžių, kiaušintakių, arba pirminės pilvaplėvės vėžys, kuris yra atsakas (visiškas arba dalinis) platinos pagrindu chemoterapija.

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - dapoksetino hidrochloridas - plėvele dengtos tabletės - 30 mg - dapoxetine

ליטא - ליטאית - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - dapoksetino hidrochloridas - plėvele dengtos tabletės - 60 mg - dapoxetine

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

האיחוד האירופי - ליטאית - EMA (European Medicines Agency)

glaxosmithkline dungarvan limited - esomeprazolas - gastroezofaginis refliuksas - protonų siurblio inhibitoriai - "nexium control" yra skirtas trumpalaikio refliukso simptomų gydymui (pvz. rėmuo ir rūgščių atpalaidavimas) suaugusiesiems.